RS56751B1 - Derivati pirolidin karboksilne kiseline kao agonisti g-protein spojenog receptora 43 (gpr43), farmaceutska kompozicija i postupci za upotrebu u lečenju metaboličkih poremećaja - Google Patents

Derivati pirolidin karboksilne kiseline kao agonisti g-protein spojenog receptora 43 (gpr43), farmaceutska kompozicija i postupci za upotrebu u lečenju metaboličkih poremećaja

Info

Publication number
RS56751B1
RS56751B1 RS20171317A RSP20171317A RS56751B1 RS 56751 B1 RS56751 B1 RS 56751B1 RS 20171317 A RS20171317 A RS 20171317A RS P20171317 A RSP20171317 A RS P20171317A RS 56751 B1 RS56751 B1 RS 56751B1
Authority
RS
Serbia
Prior art keywords
gpr43
agonists
methods
carboxylic acid
pharmaceutical composition
Prior art date
Application number
RS20171317A
Other languages
English (en)
Inventor
Hamid Hoveyda
Didier Schils
Ludivine Zoute
Julien Parcq
Original Assignee
Ogeda Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ogeda Sa filed Critical Ogeda Sa
Publication of RS56751B1 publication Critical patent/RS56751B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20171317A 2009-12-18 2010-12-17 Derivati pirolidin karboksilne kiseline kao agonisti g-protein spojenog receptora 43 (gpr43), farmaceutska kompozicija i postupci za upotrebu u lečenju metaboličkih poremećaja RS56751B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09306270 2009-12-18
US37337010P 2010-08-13 2010-08-13
US37601310P 2010-08-23 2010-08-23
PCT/EP2010/070040 WO2011073376A1 (en) 2009-12-18 2010-12-17 Pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disordersas as agonists of g- protein coupled receptor 43 (gpr43)
EP10792934.1A EP2513053B1 (en) 2009-12-18 2010-12-17 Pyrrolidine carboxylic acid derivatives as agonists of G-protein coupled receptor 43 (GPR43), pharmaceutical composition and methods for use in treating metabolic disorders

Publications (1)

Publication Number Publication Date
RS56751B1 true RS56751B1 (sr) 2018-04-30

Family

ID=42236460

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20171317A RS56751B1 (sr) 2009-12-18 2010-12-17 Derivati pirolidin karboksilne kiseline kao agonisti g-protein spojenog receptora 43 (gpr43), farmaceutska kompozicija i postupci za upotrebu u lečenju metaboličkih poremećaja

Country Status (22)

Country Link
US (6) US9695120B2 (sr)
EP (2) EP3255038A1 (sr)
JP (1) JP6144913B2 (sr)
KR (1) KR101827529B1 (sr)
CN (1) CN102812003B (sr)
AU (1) AU2010332765C1 (sr)
BR (1) BR112012018374B1 (sr)
CA (1) CA2784528C (sr)
CY (1) CY1119730T1 (sr)
DK (1) DK2513053T3 (sr)
EA (1) EA023861B3 (sr)
ES (1) ES2655091T3 (sr)
HR (1) HRP20171991T1 (sr)
HU (1) HUE038064T2 (sr)
LT (1) LT2513053T (sr)
MX (1) MX339252B (sr)
NO (1) NO2513053T3 (sr)
PL (1) PL2513053T3 (sr)
PT (1) PT2513053T (sr)
RS (1) RS56751B1 (sr)
SI (1) SI2513053T1 (sr)
WO (1) WO2011073376A1 (sr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102812003B (zh) * 2009-12-18 2015-01-21 欧洲筛选有限公司 吡咯烷羧酸衍生物、药物组合物以及在代谢紊乱中作为g-蛋白偶联受体43(gpr43)激动剂使用的方法
CA2860577C (en) 2012-01-06 2020-09-15 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds as angiotensin ii type 2 receptor antagonists
JP2015522080A (ja) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
CN105102448B (zh) 2013-02-28 2018-03-06 百时美施贵宝公司 作为rock1和rock2抑制剂的苯基吡唑衍生物
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
CA2929436C (en) 2013-11-27 2021-06-15 Euroscreen Sa Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
US10112939B2 (en) 2014-08-21 2018-10-30 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
KR101656662B1 (ko) 2014-11-18 2016-09-12 한국생명공학연구원 2-옥소-1,2,3,4-테트라하이드로피리미딘-5-카르복사미드 유도체를 유효성분으로 함유하는 대사성 질환 예방 또는 치료용 약학적 조성물
CN107033015B (zh) * 2017-06-02 2019-04-30 南京欧信医药技术有限公司 一种药物中间体的合成方法
MY196582A (en) 2018-02-13 2023-04-19 Gilead Sciences Inc PD-1/PD-L1 Inhibitors
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
ES2962674T3 (es) 2018-07-13 2024-03-20 Gilead Sciences Inc Inhibidores PD-1/PD-L1
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN114072407A (zh) 2019-04-02 2022-02-18 阿里戈斯治疗公司 靶向prmt5的化合物
WO2021018786A1 (en) 2019-07-26 2021-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ffar2 agonists for the treatment of bacterial superinfections post-viral infection
CN110981779B (zh) * 2019-11-23 2021-02-26 武汉理工大学 R-2-(2,5-二氟苯基)吡咯烷的合成方法
AU2021290168A1 (en) 2020-06-10 2023-01-05 Epics Therapeutics Synthesis of (2S,5R)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid
WO2024079206A1 (en) 2022-10-11 2024-04-18 Epics Therapeutics Polymorphs of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid and preparation processes thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542788A (en) 1968-06-12 1970-11-24 Searle & Co 1-amino-5-phenyl-2-pyrrolepropionic acid and congeners
US4006075A (en) 1975-01-06 1977-02-01 Exxon Research And Engineering Company Method of regenerating a cracking catalyst with substantially complete combustion of carbon monoxide
DE3421295A1 (de) 1984-06-08 1985-12-12 Basf Ag, 6700 Ludwigshafen Neue pyrrolidincarbonsaeurederivative, verfahren zu ihrer herstellung
JPH06104658B2 (ja) * 1988-06-23 1994-12-21 三菱化成株式会社 ピロールカルボン酸誘導体
FR2678938B1 (fr) * 1991-07-10 1993-10-08 Rhone Poulenc Rorer Sa Derives de pyrrolidine, leur preparation et les medicaments les contenant.
GB9206757D0 (en) * 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
JP3005469B2 (ja) 1996-06-05 2000-01-31 住友軽金属工業株式会社 内面スズめっき長尺銅管の製造方法
US6177464B1 (en) 1997-03-14 2001-01-23 Sepracor, Inc. Ring opening metathesis of alkenes
JP2003532726A (ja) 2000-05-05 2003-11-05 スミスクライン・ビーチャム・コーポレイション 新規抗感染症薬
US7105556B2 (en) * 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
ES2289161T3 (es) 2001-11-02 2008-02-01 Glaxo Group Limited Derivados de 4-(heteroaril de 6 miembros)-acil pirrolidina como inhibidores de hcv.
FI20030014A0 (fi) * 2003-01-03 2003-01-03 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä
US20040142379A1 (en) * 2003-01-16 2004-07-22 Carlsberg Research Laboratory Affinity fishing for ligands and proteins receptors
WO2005014534A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
AU2004263508A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
TW200528107A (en) * 2003-11-25 2005-09-01 Nissan Chemical Ind Ltd T-type calcium channel inhibitor
US7576175B2 (en) * 2004-05-27 2009-08-18 The Regents Of The University Of California Alpha-4 beta-1 integrin ligands for imaging and therapy
WO2006036688A2 (en) 2004-09-22 2006-04-06 Arena Pharmaceuticals, Inc. Gpr43 and modulators thereof for the treatment of metabolic-related disorders
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
US7425633B2 (en) * 2005-08-26 2008-09-16 National Health Research Institutes Pyrrolidine compounds
US8202902B2 (en) 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
WO2009003009A1 (en) 2007-06-26 2008-12-31 Enanta Pharmaceuticals, Inc. Substituted pyrrolidine as anti-infectives
US20090233972A1 (en) 2008-03-12 2009-09-17 Yat Sun Or Substituted heterocycles as anti-infectives
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
CN102812003B (zh) * 2009-12-18 2015-01-21 欧洲筛选有限公司 吡咯烷羧酸衍生物、药物组合物以及在代谢紊乱中作为g-蛋白偶联受体43(gpr43)激动剂使用的方法

Also Published As

Publication number Publication date
MX339252B (es) 2016-05-18
JP2013514330A (ja) 2013-04-25
US20170283376A1 (en) 2017-10-05
WO2011073376A1 (en) 2011-06-23
US20190300478A1 (en) 2019-10-03
US20130023539A1 (en) 2013-01-24
AU2010332765B9 (en) 2015-11-05
US20200347016A1 (en) 2020-11-05
US20200148636A1 (en) 2020-05-14
AU2010332765B2 (en) 2015-06-18
EP3255038A1 (en) 2017-12-13
EP2513053A1 (en) 2012-10-24
US10781171B2 (en) 2020-09-22
EA201200918A1 (ru) 2012-12-28
KR20140057690A (ko) 2014-05-13
EA023861B1 (ru) 2016-07-29
US11072582B2 (en) 2021-07-27
US10017468B2 (en) 2018-07-10
DK2513053T3 (en) 2018-01-08
ES2655091T3 (es) 2018-02-16
US9695120B2 (en) 2017-07-04
BR112012018374B1 (pt) 2021-09-21
CA2784528C (en) 2018-05-01
LT2513053T (lt) 2018-01-25
MX2012007030A (es) 2013-02-21
US10577318B2 (en) 2020-03-03
CN102812003B (zh) 2015-01-21
KR101827529B1 (ko) 2018-02-09
BR112012018374A2 (pt) 2017-03-28
EA023861B3 (ru) 2016-09-30
PL2513053T3 (pl) 2018-03-30
CA2784528A1 (en) 2011-06-23
AU2010332765C1 (en) 2016-09-29
EP2513053B1 (en) 2017-10-04
SI2513053T1 (en) 2018-02-28
NO2513053T3 (sr) 2018-03-03
US20180297944A1 (en) 2018-10-18
HUE038064T2 (hu) 2018-10-29
US10358416B2 (en) 2019-07-23
AU2010332765A1 (en) 2012-08-09
PT2513053T (pt) 2018-01-09
CY1119730T1 (el) 2018-06-27
CN102812003A (zh) 2012-12-05
AU2010332765A2 (en) 2012-08-09
JP6144913B2 (ja) 2017-06-07
HRP20171991T1 (hr) 2018-02-23

Similar Documents

Publication Publication Date Title
HUE038064T2 (hu) Pirrolidin karboxilsav származékok, mint G-protein kapcsolat receptor 43 (GPR43) agonistái, gyógyszerészeti készítmény és felhasználási eljárások metabolikus rendellenességek kezelésében
PT2334295T (pt) Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
EP2259782A4 (en) PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHOD FOR THEIR USE IN THE TREATMENT OF CELL DISEASES
ZA201008807B (en) Gip-based mixed agonists for treatment of metabolic disorders and obesity
ZA201201352B (en) Methods,compounds and compositions for delivering 1,3-propanedisulfonic acid
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
IL210577A (en) Compound 1,2,3,4-tetrahydrocyclopenta [b] indole-3-yl acetic acid, salt, hydrate and solvent, pharmaceutical, compound, salt, hydrate, solvent or pharmaceutical for use as a medicine or treatment Salt, hydrate, solvent or pharmaceutical preparation in the manufacture of a drug and process for the preparation
IL219437A (en) Converted benzamide histories, processes for their preparation, pharmacological compounds containing them and their use in the preparation of drugs for the treatment of cardiovascular diseases
HK1138840A1 (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
IL206664A0 (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
EP2360188A4 (en) HYALURONIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
IL233869A0 (en) Modified tricyclic acid derivatives as p1 s 1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
EP2217073A4 (en) METHOD FOR THE TREATMENT OF METABOLISM DISORDER AND DEPRESSION WITH DOPAMINE RECEPTOR AGONISTS
EP2257543A4 (en) MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, PROCESSING METHODS AND PREPARATION METHODS THEREOF
EP2322175A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING HYPERTENSION AND METABOLIC SYNDROME AND USE THEREOF
ZA201100041B (en) Use of indole derivatives as nurr-1 activators for treating parkinson's disease
EP2431362A4 (en) 3- (4-AMINOPHENYL) -2-FURANCARIC ACID DERIVATIVE AND PHARMACEUTICAL ACCEPTABLE SALT THEREOF
HUP0401527A3 (en) New indole and benzimidazole carboxylic acid amide derivatives, process for producing them, their use and pharmaceutical compositions containing them
HRP20130532T1 (hr) Postupak dobivanja amida karboksilnih kiselina korisnih u lijeäśenju mišiä†nih poremeä†aja
SI2155662T1 (sl) Novi derivati 3-fenil propanojske kisline, ki so aktivatorji receptorjev tipa PPAR, postopek njihove priprave in njihova uporaba v kozmetičnih ali farmacevtskih sestavkih
EP2351832A4 (en) COMPOSITION FOR INDUCTION OF TH2 LYMPHOCYTE, THERAPEUTIC COMPOSITION FOR TH2-TYPE DISEASES, AND USE THEREOF
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
GB201114785D0 (en) 2-Fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivatives, process for the preparation of sam, and process for the preparation of monofluoromethyl-coating